PRNewsWire
06 Jun 2026, 13:00 UTC · 2h ago
New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
PRNewsWire
06 Jun 2026, 13:00 UTC · 2h ago
Story key points
3 claims · impact-rated
Abbott has filed a regulatory submission with the U.S. FDA for its Libre Duo and Libre Duo 10 Day dual glucose-ketone sensing systems. — FDA clearance for a new dual-sensing product opens a significant new revenue stream and expands the addressable market for Abbott's diabetes care portfolio.
+0.60Abbott's dual glucose-ketone sensing systems received the CE Mark in May 2026. — Approval for sale in European markets provides immediate commercialization potential and validates the technology before U.S. approval.
+0.40Abbott's data indicates a sharp increase in diabetic ketoacidosis (DKA) hospitalizations across all age groups and an increasing prevalence in Type 2 diabetes patients. — This establishes a clinical need and market demand for the company's new ketone-monitoring technology.
+0.20Ticker attribution
Continue reading
6 related stories
Top 2 movers · tap to explore
Model heads
The company is presenting new clinical data and expanding its product portfolio with the development and CE Mark of the Libre Duo glucose-ketone sensing technology.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
2 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
PRNewsWire
15h ago
